Navigation Links
Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Date:2/26/2009

l-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria(R) (albiglutide), currently in Phase 3 development as a potential treatment for type 2 diabetes.

For more information about HGS, please visit the Company's website at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com This e-mail address is being protected from spam bots, you need JavaScript enabled to view it or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
2. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
3. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
6. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
7. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
10. 2008 Human Research Protection Award Recipients Announced
11. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that on ... company,s vice president of operations, was granted an option to ... per share exercise price of $0.43, the closing trading price ... to Cardica, Inc.,s Inducement Plan, which was approved by the ... of the Nasdaq Global Market for equity grants to induce ...
(Date:5/21/2015)... -- The Pharmaceutical Care Management Association (PCMA) issued ... offsets included in the Energy & Commerce Committee,s ... 21st Century Cures initiative can only be advanced by ... Medicare – then its costs outweigh any potential ... "Leveraging payments to Part D plans to ...
(Date:5/21/2015)... May 21, 2015 ... - Zwecks Leistungsvergleich zur Expertise und ... EG-Mitgliedstaaten verwiesen, in denen uneingeschränkt betriebsfähige ... Sie ein Aegate-Land: beispielsweise BELGIEN   ... Bekämpfung von Arzneimittelfälschungen (FMD) handelt es ...
Breaking Medicine Technology:Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... Corp. has signed a consent decree agreeing to correct manufacturing quality violations at its ... $175 million in unlawful profits from the sale of products that were ... , , ... , , ...
... ExpertRECALL, the leader in the field of recall logistics and ... recall logistics management in the food, drug and consumer products industries to ... with Michaels Stores, Inc. , ... Upon completion of their studies at Saint Louis University ,s ...
Cached Medicine Technology:Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3ExpertRECALL Awards First Scholarships for Product-Safety Education 2
(Date:5/24/2015)... 2015 EnviroLeather™ by LDI, a ... – a classic, rugged leather grain with enhanced ... stains, including ink, to be easily removed. The ... for corporate, healthcare, hospitality and education environments. , ... goal of developing products that are more sustainable, ...
(Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the leading ... America, Inc. (MTA) has selected IFN as a fiber ... Enterprise Sales Manager, fiber route diversity and network redundancy ... provides MTA with the diverse fiber transport from their ... and voice carriers located at Henry Street in Indianapolis, ...
(Date:5/24/2015)... A report out just last ... best option for avoiding cardiovascular disease is exercise and ... the single most powerful predictor of death and survival, ... and family history of premature death -- a finding ... lung fitness. , The Importance of Cardiovascular Screening , ...
(Date:5/23/2015)... 23, 2015 Dr. David Benvenuti, an experienced ... posted a new article to his website that ... Dr Benvenuti explained in the fascinating blog, he has ... their earlobes. , Known as “gauging,” the technique involves placing ... Dr. Benvenuti said will eventually stretch the holes out to ...
(Date:5/23/2015)... On May 16, the team at Farrell’s eXtreme ... mud obstacle run that raised funds for multiple sclerosis. ... the reason we participated was to support people living with ... eXtreme Bodyshaping. “One-hundred percent of the funds raised go to ... not only attended by eXtreme Bodyshaping staff, but members of ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
... , , BATESVILLE, ... and Radianse today announced a strategic partnership agreement to integrate ... Nurse Call system. With this move, Hill-Rom intends to ... to remove financial and technical obstacles for health care customers ...
... , VIENNA, Va., Sept. 2 ... ), a developer of vaccines for the prevention and treatment of ... of Series K convertible notes (the "Notes"). The Notes, which ... August 2006, and were convertible into common stock. , , ...
... ... (SIAC) will host Measuring Study Endpoints in Multinational Clinical Trials: Outcomes Reported from the ... LA. , ... Horsham, PA (Vocus) September 2, 2009 --The Drug Information Association (DIA) Study ...
... , SOMERSET, N.J., Sept. 2 ... and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal ... and perennial allergic rhinitis (SAR and PAR). New ASTEPRO ... convenient once-daily dosing for patients who suffer from seasonal allergies. ...
... , PARSIPPANY, N.J., Sept. 2 The following is ... Communication about the safety review of orlistat: , , ... safety review of orlistat and liver-related serious adverse events. , , ... http://www.prnewswire.com/mnr/alli/39949/ , , It,s important consumers know ...
... , , TUCSON, Ariz., Sept. 2 ... Fletcher McCusker, Chairman and Chief Executive Officer, is scheduled to present an ... Conference on Wednesday, September 9, 2009 at The Four Seasons Hotel in ... is scheduled for 9:30 a.m. ET. The presentation will be broadcast ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 4Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 5Health News:Video: FDA States Consumers Should Continue to Use alli 2Health News:Providence Service Corporation to Present at the Baird 2009 Healthcare Conference on September 9 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: